P1-1

P1-1 is a preclinical cyclic peptide antagonist targeting G protein-coupled receptor 55 (GPR55), developed by Shenzhen Turier Biotech for the treatment of liver fibrosis and liver inflammation. The drug functions by suppressing collagen secretion in hepatic stellate cells and reducing the production of reactive oxygen species (ROS). It also attenuates endoplasmic reticulum (ER) stress and inhibits mitochondria-associated hepatocyte apoptosis. Preclinical animal models, including CCl4-induced and MCD-diet-induced models, have shown that P1-1 effectively ameliorates acute liver inflammation and fibrosis, representing a novel approach to treating these conditions via GPR55 antagonism.